APX-3330
As of the edition of 20 October 2026, APX-3330 is a small molecule: in active development; acts on APEX1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2021
- Kind
- Small molecule
- Registered trials
- 2, 0 stopped early
- Disease areas
- Cancer; Eye; Heart and blood vessels; Hormones; Nutrition and metabolism
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| APEX1 | DNA repair nuclease/redox regulator APEX1 | P27695 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 1 | 1 | 0 | 0 |
| All trials | 2 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Apexian Pharmaceuticals | Lead sponsor of trials | 2018 to now |
| Ocuphire Pharma | Lead sponsor of trials | 2021 to now |